| Identification | Back Directory | [Name]
2-Fluoro-N-(3-fluoro-5-pyridin-2-yl-benzoyl)-benzenesulfonhydrazine | [CAS]
2055397-28-7 | [Synonyms]
WM-1119
WM-1110
CS-2848
WM-1119;WM 1119;WM1119;KAT6A INHIBITOR; KAT6B INHIBITOR
2-Fluoro-N-(3-fluoro-5-pyridin-2-yl-benzoyl)-benzenesulfonhydrazine
（WM-1119） 2-Fluoro-N-(3-fluoro-5-pyridin-2-yl-benzoyl)-benzenesulfonhydrazine
Benzoic acid, 3-fluoro-5-(2-pyridinyl)-, 2-[(3-fluorophenyl)sulfonyl]hydrazide
Benzoic acid, 3-fluoro-5-(2-pyridinyl)-, 2-[(2-fluorophenyl)sulfonyl]hydrazide | [EINECS(EC#)]
823-299-7 | [Molecular Formula]
C18H13F2N3O3S | [MDL Number]
MFCD31690337 | [MOL File]
2055397-28-7.mol | [Molecular Weight]
389.38 |
| Chemical Properties | Back Directory | [density ]
1.414±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:30.0(Max Conc. mg/mL);76.97(Max Conc. mM) | [form ]
A crystalline solid | [pka]
6.79±0.25(Predicted) | [color ]
Off-white to light yellow | [InChI]
1S/C18H13F2N3O3S/c19-14-10-12(16-6-3-4-8-21-16)9-13(11-14)18(24)22-23-27(25,26)17-7-2-1-5-15(17)20/h1-11,23H,(H,22,24) | [InChIKey]
QLXULUNLCRKWRD-UHFFFAOYSA-N | [SMILES]
FC1=CC(C2=NC=CC=C2)=CC(C(NNS(C3=CC=CC=C3F)(=O)=O)=O)=C1 |
| Hazard Information | Back Directory | [Uses]
WM 1119 is a highly potent and selective inhibitor of lysine acetyltransferases, KAT6A and KAT6B. | [Biological Activity]
WM-1119 is a potent and selectiveacetyl coenzyme A (Acetyl-CoA)-competitive inhibitor against MYST family histone acetyltransferases KAT6A and KAT6B (KAT6B Kd = 2.1 nM by SPRIC50 = 37 nM by activity assay; KAT7/5 Kd = 0.53/2.2 μM; no affinity toward 159 diverse biological targets). WM-1119 induces MEF G1 cell cycle arrest (1-10 μM)inhibits EMRK1184 lymphoma growth in cultures (IC50 = 250 nM) and in mice in vivo (50 mg/kg 3x or 4x i.p. per day). | [in vivo]
By day 14, the cohorts that are treated four times per day with WM-1119 have arrested tumour growth, with the exception of one mouse that does not respond. Spleen weights in the WM-1119-treatment group (treated four times per day) are substantially lower than spleen weights in the vehicle-treated group. Treatment with WM-1119 three times per day leads to a significant reduction in tumour burden and spleen weight, but is not as effective as treatment four times per day. WM-1119 is well-tolerated; mice show no generalized ill effects and weight loss is not observed. The proportion and overall number of tumour cells is substantially reduced by WM-1119 treatment (four times per day)[1]. | [IC 50]
MOZ/MORF | [storage]
Store at +4°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|